NRR: Prospective Evaluation of Patient Reported Xerostomia After Whole Brain Radiation
Study Details
Study Description
Brief Summary
The goal of this prospective observational study is to investigate whether whole brain radiation leads to measurable xerostomia from parotid gland toxicity.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
|
Detailed Description
The parotids have not been traditionally considered an organ at risk / avoidance structure in whole brain radiation. However, patients receiving whole brain radiation sometimes complain of dry mouth. Investigators hypothesize that standard whole brain radiation fields cause an acute measurable increase in xerostomia at one month post-radiation, and that the severity of xerostomia is related to the dose received by the parotids. In this study, investigators will use the validated University of Michigan Xerostomia Questionnaire to prospectively collect baseline and post-radiation xerostomia scores up to 6 months after treatment. The radiation dose to the parotids will be evaluated to assess whether there is a dose-toxicity relationship. Investigators anticipate a total accrual of 60 patients with a goal of 48 evaluable patients.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Whole Brain Radiation Patients scheduled to receive whole brain radiation with or without chemotherapy/targeted therapy. |
Outcome Measures
Primary Outcome Measures
- Measureable acute increase in xerostomia [baseline to 1 month post-treatment]
Secondary Outcome Measures
- Association of degree of change in xerostomia score and the radiation dose received by the parotid glands [baseline to 1 month post-RT]
- Effect of whole brain radiation on the time course of xerostomia [baseline and four post-radiation time points (procedure, 1 month post-RT, 3 months post-RT, 6 months post-RT).]
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Patients to be treated with whole brain radiation in 10-15 fractions to a total dose of 25-37.5 Gy for a diagnosis of brain metastases from any disease site or as prophylaxis in the treatment of potentially subclinical intracranial disease (e.g. from small cell lung cancer).
-
Has not had prior radiation that would have exposed the parotids to a significant (estimated >10 Gy mean parotid dose) level of radiation within the past one year. Patients receiving prior stereotactic radiosurgery for brain metastasis are eligible for inclusion in this trial as this form of radiation is highly conformal and exposes the parotids to minimal (estimated <1 Gy) radiation.
-
Greater than or equal to 18 years of age (no upper age limit).
-
Informed consent obtained.
Exclusion Criteria:
-
Patients receiving whole brain radiation without the use of a CT-based planning simulation.
-
Patients who are on medications known to cause dry mouth, such as anticholinergics.
-
Physically unable to communicate by paper or phone to complete the study survey.
-
Prisoners.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | University of North Carolina at Chapel Hill, Department of Radiation Oncology | Chapel Hill | North Carolina | United States | 27599 |
Sponsors and Collaborators
- UNC Lineberger Comprehensive Cancer Center
Investigators
- Principal Investigator: Kyle Wang, MD, University of North Carolina, Chapel Hill
Study Documents (Full-Text)
None provided.More Information
Additional Information:
Publications
None provided.- LCCC1540